Solésence, Inc. (SLSN) - Q3 2025 Filing Summary
Business Context and Reporting Period
Solésence, Inc. (formerly Nanophase Technologies Corporation) filed its Form 10-Q for the quarterly period ended September 30, 2025. The company, a smaller reporting company, operates as a single segment focused on science-driven beauty and life-science markets. Its primary business involves engineered materials, formulation development, and commercial manufacturing for skin health (consumer products and active pharmaceutical ingredients) and legacy advanced materials. The company uplisted to the NASDAQ Capital Market in April 2025 under the symbol SLSN.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $14.60 million | $16.87 million | $49.58 million | $39.78 million |
| Gross Profit | $3.37 million | $6.10 million | $12.63 million | $13.42 million |
| Gross Margin | 23.1% | 36.2% | 25.5% | 33.7% |
| Net Income (Loss) | $(1.12) million | $3.05 million | $1.63 million | $4.79 million |
| Diluted EPS | $(0.02) | $0.04 | $0.02 | $0.08 |
| Cash and Equivalents | $0.43 million | (Balance Sheet Data) | ||
| Total Debt (Related Party) | $15.82 million | |||
| Working Capital | $14.93 million | $3.58 million | (Calculated) |
Note: Debt figures include related party lines of credit for accounts receivable ($5.32M) and inventory ($9.50M), plus term debt ($1.00M).
Material Changes vs. Prior Period
- Revenue Mix Shift: Q3 2025 revenue declined 13.5% year-over-year, driven by a significant drop in Personal Care Ingredients revenue (down from $2.85M to $0.38M) and Advanced Materials. This was partially offset by growth in Consumer Products revenue, which rose to $13.94M from $13.60M.
- Margin Compression: Gross margin contracted significantly in Q3 2025 (23.1%) compared to Q3 2024 (36.2%). Management attributed this to manufacturing inefficiencies, facility improvements, and an inability to fully pass through raw material cost increases.
- Expense Growth: Selling, General, and Administrative (SG&A) expenses increased 58.7% in Q3 2025 ($3.07M vs $1.93M), driven by legal costs, increased allowance for credit losses, severance, and NASDAQ uplisting costs.
- Cash Flow: Operating cash flow turned negative, with net cash used in operating activities totaling $10.39 million for the nine months ended September 30, 2025, compared to a minimal outflow of $0.22 million in the prior year period. This was primarily due to a $4.84 million increase in accounts receivable and a $4.37 million decrease in deferred revenue.
- Debt Structure: The company significantly increased reliance on related-party financing. Total related-party debt outstanding rose from $5.00 million at year-end 2024 to $15.82 million as of September 30, 2025, following amendments to expand borrowing capacity on inventory and accounts receivable facilities.
Outlook, Risks, and Unusual Items
- Unusual Item (ERC Payment): In June 2025, the company received $1.73 million from the U.S. Treasury under the Employee Retention Credit (ERC) program. $1.23 million was recognized as "Other Income" in the nine-month period, significantly impacting net income. A reserve of $0.57 million was established for potential audit discrepancies.
- Legal Settlement: On October 31, 2025, the company entered a settlement agreement with Solarium Brands, LLC, agreeing to a one-time payment of $675,000 to be received by January 15, 2026, resolving disputes over previously manufactured products.
- Customer Concentration Risk: The top three customers accounted for 60% of Q3 2025 revenue. The company holds exclusive supply agreements with BASF Corporation; failure to meet performance requirements could trigger a mandatory sale of production equipment to BASF, resulting in a loss of significant revenue.
- Liquidity Concerns: Cash on hand is low ($0.43 million). The company relies heavily on related-party lines of credit secured by all unencumbered assets. Management expects capital spending for 2025 to range between $0.1 million and $1.0 million, funded by operations and existing debt facilities.
- Guidance: Management expects margins to improve as fixed manufacturing costs are absorbed by higher volume. However, they highlighted risks regarding inflation, raw material costs (specifically cerium oxide and high-purity zinc), and the ability to pass costs to customers.
Investor Verification Checklist
- Debt Covenants: Verify the specific covenants and collateral requirements of the related-party loans with Beachcorp, LLC and Strandler, LLC, given the high leverage relative to cash on hand.
- Customer Concentration: Assess the stability of the top three customers, particularly the new customer contributing 20% of Q3 revenue, and the status of the BASF supply agreement.
- Margin Sustainability: Determine if the Q3 margin compression is a one-time event due to inefficiencies or a structural shift due to raw material costs and pricing power.
- ERC Audit Risk: Confirm the status of the $0.57 million reserve regarding the ERC payment and the likelihood of an IRS audit reversing the recognized income.
- Cash Runway: Evaluate the company's ability to fund operations without further equity dilution or additional debt, given the negative operating cash flow and low cash balance.